RecruitingNCT06515899

Association of Middle Molecules Clearance With HDF Volume

Association of Middle Molecules Clearance and Clinical Parameters With Haemodiafiltration Convection Volume


Sponsor

East and North Hertfordshire NHS Trust

Enrollment

400 participants

Start Date

Jan 19, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

HDF is a dialysis technique which involves diffusion and convection. HDF with high convection volume has consistently shown to improve survival in dialysis patients in number of robust RCTs. The precise reason of this survival benefit remains unclear. The investigators hypothesize that this survival benefit with high volume HDF is related to enhanced middle molecule clearance and hemodynamic stability. However, this relationship has not been studied so far. This observational study is aimed to understand the relationship between HDF convection volume with middle molecules (Beta 2-Microglobulin) clearance during HDF. Exploring the relationship of HDF volume with middle molecules clearance has significant clinical ramifications. Only a minority of patients are able to achieve target convection volume. Understanding these relationships can rationalize the HDF prescription from convection volume-based prescription to β2-Microglobulin clearance-based prescription which may be applicable to wider range of patients. The relationship between pre-dialysis β2-Microglobulin levels and RKF offers the prospect of dispensing with pre- and post-dialysis urea and creatinine measurements and interdialytic urine collections, currently necessary for estimating RKF, thus simplifying its estimation. β2-Microglobulin reduction ratio and its component pre and post-dialysis β2-Microglobulin levels could therefore provide a composite estimate of small and middle molecule clearance and RKF.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how the volume of fluid used during hemodiafiltration — an advanced type of kidney dialysis — relates to how well it clears out harmful "middle molecules" from the blood. Middle molecules are waste products that regular dialysis does not remove as effectively, and buildup of these can cause health problems over time. **You may be eligible if...** - You are 18 years or older - You have end-stage kidney failure and have been on dialysis for at least 3 months - You have been receiving hemodiafiltration specifically for more than 4 weeks - Your doctors estimate you have a life expectancy of more than 6 months **You may NOT be eligible if...** - You are under 18 years of age - You are unable to give informed consent - Your life expectancy is estimated to be less than 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

East and North Hertfordshire NHS Trust

Stevenage, Hertfordshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06515899


Related Trials